CUVITRU (Baxalta US Inc.)
Welcome to the PulseAid listing for the CUVITRU drug offered from Baxalta US Inc.. This Human Immunoglobulin G [EPC],Passively Acquired Immunity [PE],Antigen Neutralization [MoA],Immunoglobulins [Chemical/Ingredient] pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.
| LABELER NAME / MANUFACTURER: | Baxalta US Inc. |
| NON-PROPRIETARY NAME: | Human Immunoglobulin G |
| SUBSTANCE NAME: | HUMAN IMMUNOGLOBULIN G |
| TYPE: | PLASMA DERIVATIVE |
| PHARMA CLASS: | Human Immunoglobulin G [EPC],Passively Acquired Immunity [PE],Antigen Neutralization [MoA],Immunoglobulins [Chemical/Ingredient] |
| ROUTE: | INTRAVENOUS; SUBCUTANEOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2016-10-18 |
| END MARKETING DATE: | 0000-00-00 |
CUVITRU PLASMA DERIVATIVE Details:
| Item Description | CUVITRU from Baxalta US Inc. |
| LABELER NAME: | Baxalta US Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 1(g/5mL) |
| START MARKETING DATE: | 2016-10-18 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0944-2850_a75cce13-0654-4513-bdd0-a3f50a36d47b |
| PRODUCT NDC: | 0944-2850 |
| APPLICATION NUMBER: | BLA125596 |
Other HUMAN IMMUNOGLOBULIN G Pharmaceutical Manufacturers / Labelers:
